Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.63 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sematilide SCHEMBL122585 | 0.99 | POLB (0.67) | ALDH1A1NFKB1KCNH2POLBBLM | |
| Sematilide SCHEMBL9274272 | 0.97 | POLB (0.66) | ALDH1A1NFKB1KCNH2POLBBLM | |
| SCHEMBL10642818 | 0.92 | HDAC3 (0.59) | ALDH1A1NFKB1KCNH2POLBBLM | |
| SCHEMBL10642513 | 0.91 | ALDH1A1 (0.55) | ALDH1A1NFKB1KCNH2POLBBLM | |
| SCHEMBL10645045 | 0.90 | SMN1; SMN2 (0.57) | ALDH1A1NFKB1KCNH2POLBBLM | |
| SCHEMBL10920006 | 0.90 | KCNH2 (0.60) | ALDH1A1NFKB1KCNH2POLBBLM | |
| SCHEMBL9826682 | 0.90 | ALDH1A1 (0.55) | ALDH1A1NFKB1KCNH2POLBBLM | |
| Bromide SCHEMBL10647145 | 0.89 | SMN1; SMN2 (0.56) | ALDH1A1NFKB1KCNH2POLBBLM | |
| SCHEMBL10645163 | 0.89 | KCNH2 (0.61) | ALDH1A1NFKB1KCNH2POLBBLM | |
| SCHEMBL10886881 | 0.89 | ALDH1A1 (0.67) | ALDH1A1NFKB1KCNH2POLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 815 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240099984-A1 | A BIODISSOLVABLE FILM FOR LOCALIZED AND EFFICIENT TREATMENT OF VULVODYNIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2024-03-28 | — | — | US | claimed |
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | claimed |
| WO-2016010844-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE | TARIX PHARMACEUTICALS LTD (US) | 2016-01-21 | — | — | WO | claimed |
| WO-2015197079-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2015-12-30 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150064234-A1 | 4-AMINOPYRIDINE AS A THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-03-05 | — | — | US | claimed |
| US-20150045305-A1 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | claimed |
| EP-2830620-A1 | 4 AMINOPYRIDINE AS A THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | The Trustees of Columbia University in the City of New York (US) | 2015-02-04 | — | — | EP | claimed |
| CN-104334174-A | 4-aminopyridines as therapeutic agents for spinal muscular atrophy | UNIV COLUMBIA | 2015-02-04 | — | — | CN | claimed |
| EP-2806865-A1 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS | Gilead Sciences, Inc. (US) | 2014-12-03 | — | — | EP | claimed |
| CN-1263454-A | Device and method for treatment of dysmenorrhea | UMD INC (US) | 2000-08-16 | — | — | CN | claimed |
| WO-1999064050-A9 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0988009-A1 | DEVICE AND METHOD FOR TREATMENT OF DYSMENORRHEA | UMD, Inc. (US) | 2000-03-29 | — | — | EP | claimed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1998056323-A1 | DEVICE AND METHOD FOR TREATMENT OF DYSMENORRHEA | UMD, INC. (US) | 1998-12-17 | — | — | WO | claimed |
| EP-0752859-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A CLASS III ANTIARRHYTHMIC AGENT AND A CLASS IV ANTIARRHYTHMIC AGENT | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1997-01-15 | — | — | EP | claimed |
| WO-1995026726-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A CLASS III ANTIARRHYTHMIC AGENT AND A CLASS IV ANTIARRHYTHMIC AGENT | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1995-10-12 | — | — | WO | claimed |
| EP-0158775-B1 | SUBSTITUTED SULFONAMIDOBENZAMIDES, ANTIARRYTHMIC AGENTS AND COMPOSITIONS THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-04-20 | — | — | EP | claimed |
| EP-0158775-A1 | Substituted sulfonamidobenzamides, antiarrythmic agents and compositions thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-10-23 | — | — | EP | claimed |
| US-4544654-A | Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof | SCHERING A.G. (DE) | 1985-10-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045305-A1 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS | KCNH1, KCNN3, KCNB2 | ALDH1A1 2395/4885NFKB1 1133/4885KCNH2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.